Presentation #1:
Establishing the Irish Diabetic Retinopathy Screening and Treatment Program (RetinaScreen)
Description #1:
Cover the rationale for establishing a screening programme. The steps to developing a coherent screening programme. The clinical and economic argument along with the role of advocacy. The link between an effective screen and subsequent treatment referral. The steps to the development of quality and clinical standards and ensuring that they are applied.
Objectives #1:
- Awareness of effectiveness of population screening to limit sight loss due to diabetic retinopathy
- Method to establish a national diabetic retinopathy screening and treatment programme IT and management needs
- Application of evidence based quality and clinical standards to a population based screening and treatment programme.
Presentation #2:
MicroRNA Biomarkers in Age Related Macular Degeneration
Description #2:
Present a series of studies on the search, validation, in vitro analysis and pathway prediction of potential serum microRNA biomarkers as candidates to predict diagnosis and prognosis in AMD.
Objectives #2:
- An overview of the clinical biomarkers
- The techniques to search for candidate serum biomarkers in AMD
- Application of DIANA lab-mirPath to predict a number of significant pathways in pathogenesis of AMD
- Community eye care professionals
- Full time faculty
- Residents
- Fellow ophthalmologists
- Optometrists
- Ophthalmic photographers
At the conclusion of this activity, I will be able to:
- Awareness of effectiveness of population screening to limit sight loss due to diabetic retinopathy
- Method to establish a national diabetic retinopathy screening and treatment programme IT and management needs
- Application of evidence based quality and clinical standards to a population based screening and treatment programme.
- An overview of the clinical biomarkers
- The techniques to search for candidate serum biomarkers in AMD
- Application of DIANA lab-mirPath to predict a number of significant pathways in pathogenesis of AMD
David Keegan, PhD FRCOphth FRCSI(Oph)
Consultant Ophthalmic Surgeon
Mater Misericordiae University Hospital and Mater Private Hospital
Honorary Consultant Vitreo-retinal Surgeon
Temple Street Children's University Hospital
National Clinical Lead for Diabetic RetinaScreen Programme
Name | Company | Role |
David Keegan, PhD, FRCOphth, FRCSI(Oph) | Novartis | Administrator |
| Bayer | Administrator |
| Diabetes Federation of Ireland | Speaker |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
Contact
- 1.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.25 Hours of ParticipationHours of Participation credit.